Bio-Rad Labs (NYSE: BIO) reported Q2 EPS of $3.54, $0.88 better than the analyst estimate of $2.66. Revenue for the quarter came in at $715.9 million versus the consensus estimate of $631.78 million.

2021 Financial Outlook:

For the full year 2021, the company has updated its guidance and now anticipates non-GAAP currency-neutral revenue growth between 10.0 to 10.5 percent and an estimated non-GAAP operating margin of approximately 19.0 percent. Management will discuss this outlook in greater detail on the second-quarter 2021 financial results conference call.

For earnings history and earnings-related data on Bio-Rad Labs (BIO) click here.